Finerenone Beyond Diabetic CKD
What FIND-CKD Proves - and What an Expanded Indication Would Still Leave Unresolved
Executive Summary
The Phase 3 FIND-CKD trial establishes that mineralocorticoid-receptor antagonism has renal activity beyond diabetic kidney disease. In adults with albuminuric chronic kidney disease (CKD) without diabetes, finerenone slowed the total estimated glomerular filtration rate (eGFR) decline by 0.7 ml/min/1.73 m2 per year relative to placebo and reduced albuminuria. A prespecified cardiorenal composite also favored finerenone, with a 3-percentage-point absolute risk reduction over 32 months.[1]
Those findings are clinically relevant, but their meaning must be calibrated. The primary result corresponds to approximately 1.9 eGFR units preserved over the trial period. Both treatment groups continued to lose kidney function. Finerenone did not repair lost nephrons, reverse established sclerosis, or treat the initiating cause of glomerular disease. It is best understood as a non-curative, progression-modifying treatment directed at a shared downstream pathway of inflammation and fibrosis.
The larger strategic limitation is the comparator. Nearly all FIND-CKD participants received a maximally tolerated angiotensin-converting enzyme inhibitor (ACEi) or angiotensin-receptor blocker (ARB), but only about 17% used a sodium-glucose cotransporter-2 (SGLT2) inhibitor at baseline.[1] Current KDIGO guidance recommends an SGLT2 inhibitor for adults with CKD, eGFR at least 20 ml/min/1.73 m2, and urine albumin-to-creatinine ratio (UACR) at least 200 mg/g - essentially the phenotype enrolled in FIND-CKD.[3] The trial therefore demonstrates finerenone's activity mainly over renin-angiotensin-system inhibition, but incompletely defines its marginal value over the contemporary combination of ACEi/ARB plus SGLT2 inhibition and disease-specific treatment.
At the current U.S. wholesale acquisition cost, the drug would cost approximately $21.95 million per 1,000 patients over 32 months. Applied directly to the observed 3% absolute reduction in the composite endpoint, that equals roughly $732,000 in gross drug-acquisition cost per composite event avoided. This is not a cost-per-QALY estimate, and the composite includes outcomes with very different clinical and economic values. Nevertheless, it shows why reimbursement will depend on price, patient selection, and the durability of dialysis and cardiovascular-event avoidance - not merely on statistical significance.
BBIU central judgment: FIND-CKD may be sufficient to support a regulatory expansion, but it is not sufficient to establish unrestricted reimbursement or to justify valuing the entire non-diabetic CKD population as an addressable market. Regulatory success, clinical relevance, payer value, and commercial uptake remain separate decision layers.
1. The Decision Problem Is Larger Than the Primary Endpoint
Finerenone is already established in CKD associated with type 2 diabetes and, in the United States, in heart failure with left ventricular ejection fraction of at least 40%. As of August 2026, the FDA label does not include CKD without diabetes.[5] Bayer has stated that it intends to provide FIND-CKD data to health authorities for regulatory assessment.[12]
An expanded indication would be strategically important. It would reposition finerenone from a therapy anchored primarily to diabetic CKD into a broader cardiorenal platform addressing common mechanisms across several CKD etiologies. But the central decision is not simply whether the drug produces a statistically detectable effect. Decision-makers must determine:
Whether the absolute clinical effect is meaningful for the individual patient.
Whether the effect persists when finerenone is added to the current multidrug standard of care.
Which non-diabetic CKD etiologies and risk groups are represented by the evidence.
Whether the safety and monitoring burden is acceptable in routine practice.
Whether long-term avoidance of kidney failure and cardiovascular events offsets the acquisition cost.
Whether regulatory expansion can translate into reimbursed and sustained commercial uptake.
These questions cannot be collapsed into the 0.7 ml/min/1.73 m2 per-year difference reported for the primary endpoint.
2. What FIND-CKD Actually Demonstrated
FIND-CKD was a multinational, randomized, double-blind, placebo-controlled Phase 3 trial funded by Bayer. It enrolled 1,584 adults with CKD without diabetes, eGFR of 25 to less than 90 ml/min/1.73 m2, and UACR of 200 to 3,500 mg/g. Participants received finerenone 10 or 20 mg once daily or placebo in addition to a stable, maximally tolerated ACEi or ARB.[1,2]
The mean baseline eGFR was approximately 46.8 ml/min/1.73 m2. Over 32 months:
Annual eGFR decline was -3.3 ml/min/1.73 m2 with finerenone.
Annual eGFR decline was -4.0 ml/min/1.73 m2 with placebo.
The between-group difference was 0.7 ml/min/1.73 m2 per year (95% CI, 0.3 to 1.1; p<0.001).
The result represents approximately 17.5% relative slowing of decline, but only about 1.9 eGFR units preserved over 32 months.
The key secondary composite - kidney failure, sustained eGFR decline of at least 57%, hospitalization for heart failure, or cardiovascular death - occurred in 13.9% of participants receiving finerenone and 16.9% receiving placebo. The hazard ratio was 0.77 (95% CI, 0.60 to 0.99), corresponding to an absolute risk reduction of approximately 3 percentage points and a number needed to treat of about 33 over the trial period.[1]
Finerenone also reduced albuminuria substantially. That finding supports a genuine biological effect on glomerular injury and the pathways associated with CKD progression.
Statistical success is not the same as large patient-level benefit
The primary endpoint was positive and statistically robust. The correct criticism is therefore not that the trial failed. The issue is that a relative description can make the magnitude appear larger than the absolute functional preservation experienced during the observed period.
The secondary composite improves the clinical interpretation because it includes harder outcomes. However, it also combines events of unequal significance. A sustained laboratory decline, kidney failure, heart-failure hospitalization, and cardiovascular death do not carry the same patient value or cost. In addition, the separate kidney composite narrowly missed conventional statistical significance, while the cardiovascular estimate was based on few events and had a wide confidence interval. The combined result is supportive, but it does not establish the contribution of each component with equal certainty.
The most defensible interpretation is that finerenone produces a real but partial attenuation of progression. It does not convert progressive CKD into remission.
3. Non-Diabetic CKD Is Not One Disease
The potential new indication spans a heterogeneous group of disorders. Non-diabetic CKD includes immune-mediated glomerular disease, podocytopathies, hypertensive and ischemic nephropathy, genetic disease, and toxic or obstructive injury. Their initiating mechanisms differ, even when their late structural consequences converge.
Progressive CKD commonly follows a self-reinforcing sequence:
Initial injury causes irreversible nephron loss.
Surviving nephrons compensate through hyperfiltration and increased intraglomerular pressure.
Mechanical stress damages podocytes and the filtration barrier.
Albumin and other filtered proteins activate tubular inflammatory and profibrotic signaling.
Microvascular loss, hypoxia, oxidative stress, and mitochondrial dysfunction promote tubular atrophy and fibrosis.
Glomerulosclerosis and tubulointerstitial fibrosis produce further nephron loss.
This common pathway does not erase disease-specific biology. In IgA nephropathy, pathogenic immune complexes and complement activation initiate injury. In primary focal segmental glomerulosclerosis (FSGS), podocyte dysfunction may involve circulating factors. Secondary and genetic FSGS reflect adaptive, toxic, infectious, or genetic podocyte stress. Hypertensive and ischemic nephropathy begin with vascular injury, reduced perfusion, and loss of autoregulatory reserve.
The therapeutic consequence is fundamental: a drug that slows a shared downstream pathway cannot automatically substitute for treatment directed at the initiating disease.
4. Finerenone Targets an Amplifier, Not the Root Cause
The mineralocorticoid receptor is expressed in epithelial and non-epithelial renal and cardiovascular tissues. Excessive activation promotes sodium retention, endothelial dysfunction, oxidative stress, inflammatory-cell recruitment, fibroblast activation, and extracellular-matrix deposition. Aldosterone breakthrough may allow this signaling to persist despite ACEi or ARB therapy.[5,6]
Finerenone is a selective, nonsteroidal mineralocorticoid-receptor antagonist. Its expected renal effects include reduced podocyte and endothelial injury, lower albumin leakage, reduced inflammatory signaling, and slower accumulation of glomerular and tubulointerstitial fibrosis. The FDA label describes finerenone as blocking MR-mediated sodium reabsorption and MR overactivation in epithelial and non-epithelial tissues.[5]
Finerenone does not:
Remove pathogenic IgA immune complexes.
Directly suppress complement activation.
Neutralize a potential circulating FSGS factor.
Correct a genetic podocyte defect.
Restore lost nephrons.
Reverse established glomerulosclerosis.
Replace biopsy-guided immunological or disease-specific treatment.
Calling finerenone purely palliative would be imprecise because it changes the rate of disease progression. Calling it curative would be equally incorrect. It is a supportive, disease-modifying therapy that targets one downstream contributor to progression.
5. The Contemporary Treatment Algorithm Creates the Main Evidence Gap
Current management of albuminuric CKD without diabetes combines general kidney protection with treatment of the underlying cause. The practical sequence includes:
Confirming chronicity, etiology, eGFR, albuminuria, and kidney-failure risk.
Sodium restriction, appropriate protein intake, exercise, smoking cessation, and avoidance of nephrotoxins.
Blood-pressure control and management of dyslipidemia, anemia, metabolic acidosis, and mineral-bone disease.
A maximally tolerated ACEi or ARB for albuminuric disease, with creatinine and potassium monitoring.
An SGLT2 inhibitor when eGFR and albuminuria meet guideline criteria.
Disease-specific therapy for IgA nephropathy, primary FSGS, or other immune-mediated disease when indicated.
Nephrology referral and preparation for kidney-replacement therapy in high-risk advanced disease.
KDIGO 2024 gives a 1A recommendation for an SGLT2 inhibitor in adults with CKD, eGFR at least 20 ml/min/1.73 m2, and UACR at least 200 mg/g, irrespective of diabetes.[3] EMPA-KIDNEY independently demonstrated cardiorenal benefit in a broad CKD population that included a majority without diabetes.[4]
Because FIND-CKD required UACR of at least 200 mg/g and eGFR of at least 25 ml/min/1.73 m2, almost the entire trial phenotype would now be expected to receive an SGLT2 inhibitor unless contraindicated or intolerant. Yet only about 17% used one at baseline.[1]
The relevant contemporary comparison is therefore:
Optimized ACEi/ARB + SGLT2 inhibitor + disease-specific therapy
versus
The same regimen + finerenone
FIND-CKD did not adequately power this comparison. A consistent subgroup result among SGLT2 users may support biological compatibility, but it cannot replace a sufficiently sized evaluation of incremental benefit.
Finerenone's most plausible future position is as an additional or third kidney-protective pillar for patients with persistent albuminuria and high residual progression risk after optimized therapy. That positioning is clinically coherent, but the magnitude of the marginal benefit remains incompletely quantified.
6. Hyperkalemia Is the Principal Safety and Implementation Constraint
Overall adverse-event and serious-adverse-event rates were similar between groups in FIND-CKD. The principal treatment-specific difference was hyperkalemia:[1]
Hyperkalemia: 17.0% with finerenone versus 13.3% with placebo.
Absolute excess risk: 3.7 percentage points.
Approximate number needed to harm: 27.
Discontinuation because of hyperkalemia: 1.5% versus 0.1%.
Hyperkalemia-related hospitalization: 0.9% versus 0.6%.
No fatal hyperkalemia was reported.
The overall safety profile was therefore manageable under trial monitoring, but hyperkalemia cannot be treated as an incidental laboratory finding. CKD limits potassium excretion, and the risk can rise rapidly during dehydration, acute kidney injury, infection, metabolic acidosis, or exposure to interacting medications.
ACEi/ARB therapy does not neutralize the potassium effect
ACE inhibitors and ARBs reduce angiotensin-II-mediated aldosterone production. Finerenone blocks activation of the mineralocorticoid receptor by the aldosterone that remains. Both mechanisms reduce distal potassium secretion. Their kidney-protective effects may be complementary, but their potassium effects are additive.
SGLT2 inhibitors and kaliuretic diuretics may partially reduce hyperkalemia risk in selected patients, but they do not eliminate the need for surveillance. The FDA label requires serum potassium and eGFR measurement before initiation, repeat potassium testing approximately four weeks after initiation or dose adjustment, and periodic monitoring thereafter. Treatment should not be initiated when serum potassium exceeds 5.0 mEq/L, and initiation below eGFR 25 ml/min/1.73 m2 is not recommended under the current U.S. label.[5]
Finerenone is predominantly metabolized through CYP3A4. Strong CYP3A4 inhibitors are contraindicated; moderate or weak inhibitors require additional monitoring, and grapefruit should be avoided. Potassium supplements, potassium-containing salt substitutes, potassium-sparing drugs, NSAIDs, trimethoprim, acute volume depletion, and metabolic acidosis can further increase risk.[5]
Arrhythmia risk is indirect, not a demonstrated direct cardiac toxicity
Severe hyperkalemia can produce conduction abnormalities, ventricular arrhythmias, asystole, and sudden death. A normal electrocardiogram does not reliably exclude dangerous hyperkalemia. However, FIND-CKD did not demonstrate an increase in arrhythmias attributable to hyperkalemia. The FDA label also reports no clinically relevant QT prolongation at twice the maximum approved recommended dose.[5,7]
Any arrhythmia burden attributed to an expanded indication should therefore be modeled as a sensitivity scenario, not presented as an observed trial outcome.
The insulin issue requires qualification
Insulin activates cellular potassium uptake and provides a rapid physiological buffer while the kidneys eliminate a potassium load. Absolute or effective insulin deficiency, hyperglycemia, hyperosmolarity, and acidosis may weaken this buffer and worsen extracellular potassium elevation. This can be important in untreated type 1 diabetes, advanced insulinopenic type 2 diabetes, or acute metabolic decompensation.
It does not follow that every patient with diabetes is automatically less protected. Early type 2 diabetes is often associated with hyperinsulinemia and insulin resistance rather than absolute insulin deficiency. Intravenous insulin can temporarily shift potassium into cells during acute hyperkalemia, but it does not remove potassium from the body. Rebound can occur unless potassium is eliminated through renal excretion, binders, or dialysis. CKD also reduces insulin clearance and increases the risk of delayed hypoglycemia after treatment.[7]
7. Pharmacoeconomics: The Acquisition Cost Dominates the Trial-Horizon Model
No peer-reviewed cost-effectiveness analysis specific to FIND-CKD was identified as of August 2026. The following calculations are therefore transparent scenario analyses based on the trial results and public U.S. pricing, not a formal lifetime cost-per-QALY model.
The published U.S. wholesale acquisition cost is approximately $685.81 for 30 tablets, equivalent to:[10]
Approximately $8,230 per patient-year.
Approximately $21,946 per patient over 32 months.
Approximately $21.95 million per 1,000 treated patients over the FIND-CKD period.
The 3-percentage-point absolute reduction in the cardiorenal composite corresponds to approximately 30 events avoided per 1,000 patients, or an NNT of about 33. Dividing gross acquisition cost by composite events avoided produces approximately $732,000 per event avoided.
This figure is not a valid ICER. It does not incorporate rebates, quality-adjusted survival, monitoring costs, event costs, or long-term dialysis avoidance. It also treats every component of the composite as economically equivalent. Its value is diagnostic: it shows that the economic argument cannot be sustained by the observed trial-horizon event count alone.
The 0.7 ml/min/1.73 m2 annual slope difference corresponds to approximately 1.87 eGFR units preserved over 32 months, or roughly $11,700 in gross acquisition cost per eGFR unit preserved. This is also not a validated economic endpoint. It illustrates the same structural issue: value must come from future hard outcomes, not from the surrogate unit itself.
Hyperkalemia and potential arrhythmia costs
Applied to 1,000 treated patients, FIND-CKD implies approximately 37 additional hyperkalemia events, 14 additional discontinuations, and three additional hyperkalemia-related hospitalizations over 32 months.
A U.S. claims analysis in CKD with type 2 diabetes estimated acute costs of $31,212 for hospitalized hyperkalemia and $1,782 for non-hospitalized hyperkalemia. Applying those historical estimates to three hospitalized and 34 non-hospitalized excess events produces an illustrative cost of approximately $154,000 per 1,000 patients.[9] This estimate is not directly transferable without adjustment: the data were drawn from a diabetic CKD population, an earlier cost period, and one payer environment. It also excludes routine laboratory testing, repeat visits, dose changes, and potassium binders.
Because no attributable arrhythmia signal was observed, arrhythmia costs belong in sensitivity analysis. Using $30,500 per arrhythmia hospitalization as an imperfect proxy:[9]
If 1% of excess hyperkalemia events caused an arrhythmia admission: approximately $11,000 per 1,000 treated patients.
At 5%: approximately $56,000.
At 10%: approximately $113,000.
These are stress-test assumptions, not forecasts. They should not automatically be added to hyperkalemia hospitalization costs because doing so may double count the same episode.
The lifetime model hinges on dialysis delay
The strongest possible economic justification is that a persistent slope difference delays kidney failure and dialysis, which are extremely costly and associated with substantial loss of quality and length of life. A simple linear extrapolation from the mean eGFR and the observed total slopes could imply roughly 1.7 years of delayed progression to an eGFR threshold of 15 ml/min/1.73 m2.
That delay was not observed in FIND-CKD. It assumes that:
eGFR decline remains linear.
The treatment effect does not wane.
Patients remain adherent for many years.
The same effect persists on top of widespread SGLT2 use.
Reaching a laboratory threshold maps directly to dialysis initiation.
Competing mortality and treatment discontinuation do not materially alter the result.
This is the critical economic uncertainty. In its review of finerenone for diabetic CKD, CADTH's exploratory analyses ranged from approximately C$70,052 to C$2.99 million per QALY depending largely on assumptions about cardiovascular mortality, dialysis reduction, and treatment durability. Price reductions of approximately 23% to more than 55% were required in different scenarios to reach C$50,000 per QALY.[8] FIND-CKD provides less direct hard-outcome evidence than the diabetic-CKD program; payer confidence should therefore not be assumed to be greater.
8. Indication Expansion: Commercial Opportunity Versus Addressable Reality
For Bayer, non-diabetic CKD is a strategically attractive lifecycle extension. Kerendia generated EUR829 million in 2025 sales, up 79% from 2024, with growth led by the United States and China.[11] A broader renal label could strengthen the product's position across CKD and heart failure and extend its relevance beyond a diabetes-centered prescribing pathway.
The potential budget impact is also substantial. Every additional 100,000 U.S. patients treated for one year would represent approximately $823 million in gross wholesale acquisition cost. That number is payer expenditure at list price - not Bayer net revenue. Rebates, distribution, abandonment, adherence, coverage restrictions, and geographic pricing materially separate gross WAC from recognized sales.
Commercial models should not multiply the current price by the global or U.S. prevalence of CKD. FIND-CKD did not enroll the entire non-diabetic CKD population. A credible initial market must reflect:
Persistent albuminuria in the studied range.
eGFR within the evidence base.
Residual progression risk despite optimized therapy.
Acceptable baseline potassium.
Exclusion of etiologies and active immune disease not represented in the trial.
Access to laboratory monitoring.
Payer requirements and specialist prescribing behavior.
The paradox is straightforward: the indication expansion can be highly valuable to the manufacturer while remaining economically difficult for the payer. The same prevalence that creates commercial upside creates a large aggregate budget exposure when the individual treatment effect is modest and the therapy is additive rather than substitutive.
9. Conclusions for Decision-Makers, CEOs, and Investors
For regulators and health-technology assessors
FIND-CKD provides evidence of activity across non-diabetic albuminuric CKD and a plausible shared mechanism. The primary endpoint is statistically persuasive, but the label and reimbursement population should remain aligned with the phenotype actually studied. Extrapolation to non-albuminuric CKD, eGFR below 25, active immunological disease, or the entire non-diabetic CKD population is not justified by this trial.
For payers and health systems
The most defensible initial coverage strategy would prioritize patients with persistent albuminuria and high residual risk despite maximally tolerated ACEi/ARB and an SGLT2 inhibitor, unless contraindicated. Coverage may reasonably require baseline potassium thresholds, documented monitoring, specialist involvement, and price concessions or outcomes-based arrangements.
The cost of hyperkalemia and possible arrhythmia does not dominate the economic model. Drug acquisition does. The pivotal payer question is whether long-term kidney-failure and dialysis avoidance are sufficiently durable to offset years of additive treatment cost.
For Bayer and other manufacturers
Regulatory approval would validate the platform but would not resolve the access problem. Durable adoption will depend on:
Incremental efficacy on top of SGLT2 inhibitors.
Identification of subgroups with larger absolute benefit.
Sustained reduction in kidney failure and dialysis.
Real-world persistence and manageable hyperkalemia rates.
A price compatible with layered CKD therapy.
The future CKD market will increasingly judge each product by the benefit it adds to an already effective multidrug regimen, not simply by placebo-controlled efficacy.
For investors
A positive regulatory decision would be an important asset-validation event, but investors should not model expansion by applying list price to headline CKD prevalence. The principal valuation variables are the final label, payer restrictions, negotiated net price, guideline placement, uptake among nephrologists, persistence, use with SGLT2 inhibitors, and confirmation of long-term hard outcomes.
The largest valuation inflection would not be approval alone. It would be evidence that finerenone delivers clinically meaningful and economically defensible benefits on top of contemporary standard care.
Final BBIU Assessment
FIND-CKD succeeds scientifically: it shows that mineralocorticoid-receptor activation contributes to progression outside diabetic CKD and that blocking this pathway can preserve a measurable amount of kidney function. The effect is neither fictitious nor transformative.
Finerenone should be regarded as a non-curative, progression-modifying addition to treatment. Its potential indication expansion is strategically valuable, but broad clinical and commercial claims must remain narrower than the headline category of non-diabetic CKD.
The central unresolved issue is marginal value. The trial establishes benefit primarily over ACEi/ARB therapy in a population with limited baseline SGLT2 use. Contemporary practice requires a different comparison: optimized multidrug and disease-specific therapy with versus without finerenone.
Until that incremental benefit and its long-term effect on dialysis are better defined, the evidence supports targeted adoption more strongly than unrestricted expansion. Regulatory success is plausible. Economic success will depend on price, selection, and proof that a modest slope difference becomes a durable hard-outcome benefit.
BBIU INSTITUTIONAL ANALYSIS | FINERENONE BEYOND DIABETIC CKD
References
Heerspink HJL, et al. Finerenone in Persons with Chronic Kidney Disease without Diabetes. New England Journal of Medicine. 2026. Source
ClinicalTrials.gov. FIND-CKD (NCT05047263). Source
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024;105(Suppl 4S):S117-S314. Source
The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 2023;388:117-127. Source
U.S. Food and Drug Administration. KERENDIA (finerenone) Prescribing Information. Revised July 2025. Source
Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2020;383:2219-2229. Source
Kim MJ, Valerio C, Knobloch GK. Potassium Disorders: Hypokalemia and Hyperkalemia. American Family Physician. 2023;107(1):59-70. Source
Canadian Agency for Drugs and Technologies in Health. Pharmacoeconomic Review: Finerenone (Kerendia). 2023. Source
Betts KA, Song J, Faust E, et al. Medical Costs for Managing Chronic Kidney Disease and Related Complications in Patients With Chronic Kidney Disease and Type 2 Diabetes. American Journal of Managed Care. 2021;27:S369-S374. Source
Myshko D. Priority Review Granted for Kerendia in Type 1 Diabetes and Kidney Disease. Managed Healthcare Executive. May 21, 2026. Source
Bayer AG. Annual Report 2025 - Pharmaceuticals. March 4, 2026. Source
Bayer AG. Bayer's Finerenone Significantly Reduced Kidney Function Decline and a Composite of Cardiovascular-Kidney Outcomes Versus Placebo in Patients with Non-Diabetic Chronic Kidney Disease. June 5, 2026. Source
